Skip to main content
Clinical Trials/PACTR202403843973020
PACTR202403843973020
Recruiting
Phase 3

High Dose Dexamethasone versus Prednisone as First Line Therapy in Newly diagnosed Immune Thrombocytopenic Purpura in Children

faculty of medicine of tanta university0 sites60 target enrollmentNovember 5, 2023

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Haematological Disorders
Sponsor
faculty of medicine of tanta university
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 5, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Children aged 1–18 years with newly diagnosed primary ITP before starting any treatment having platelet count \< 30,000 /µ

Exclusion Criteria

  • 1\-Patients with secondary ITP including leukemia, drugs, lupus erythematous, hepatitis C, anti\-phospholipid syndrome.
  • 2\-Ptaients with ITP who received any treatment.

Outcomes

Primary Outcomes

Not specified

Similar Trials